Niacin-based pharmaceutical compositions
OwnerH. Thomas Hightinventor
Life of this patent
Estimating the term…
Abstract
The disclosure relates generally to niacin-based pharmaceutical compositions that include at least one pharmaceutical agent capable of treating a niacin-induced side-effect. Accordingly, one aspect of this disclosure is a pharmaceutical composition for delivering niacin to a patient in need thereof, wherein the composition comprises a therapeutic dose of niacin and a therapeutically effective dose of at least one pharmaceutical agent capable of reducing an adverse side-effect of niacin in the patient, and wherein the pharmaceutical agent is delivered to the patient jointly with the niacin, preferably as a single dosage pill or tablet.
Claims23
A pharmaceutical composition for delivering niacin to a patient in need thereof, wherein the composition comprises a therapeutic dose of niacin and a therapeutically effective dose of at least one pharmaceutical agent capable of reducing an adverse side-effect of niacin in the patient, and wherein the pharmaceutical agent is delivered to the patient jointly with the niacin.
A method of reducing niacin-induced flushing while protecting the gastrointestinal tract in a patient receiving niacin for a lipid disorders, comprising administering to the recipient patient a therapeutic composition comprising niacin, a non-steroidal anti-inflammatory drug, and a gastrointestinal protecting agent.
A method of treating niacin-induced hyperglycemia in patients who are not diabetic comprising delivering to the patient a single therapeutic dose comprising a therapeutically effective dose of niacin and a therapeutically effective dose of a pharmaceutical agent capable of lowering blood sugar levels with a blood sugar-lowering agent in one pill.
A method of treating niacin-induced chronic phase histamine-mediated niacin side effects by combining niacin with an histamine blocking agent in one pill.
Dependencies are inferred from the claim text.